BIOMAT Database Logo BIOMAT Database Logo

Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma. 1983

C J Coonley, and R P Warrell, and D J Straus, and C W Young

UI MeSH Term Description Entries
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015255 Idarubicin An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA. 4-Demethoxydaunorubicin,4-Desmethoxydaunorubicin,IMI-30,Idarubicin Hydrochloride,NSC-256439,4 Demethoxydaunorubicin,4 Desmethoxydaunorubicin,Hydrochloride, Idarubicin,IMI 30,IMI30,NSC 256439,NSC256439

Related Publications

C J Coonley, and R P Warrell, and D J Straus, and C W Young
Phase II trial of 4-demethoxydaunorubicin in patients with advanced malignant melanoma.
January 1985, Cancer treatment reports,
C J Coonley, and R P Warrell, and D J Straus, and C W Young
Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.
July 1986, Cancer treatment reports,
C J Coonley, and R P Warrell, and D J Straus, and C W Young
Weekly oral 4-demethoxydaunorubicin in patients with relapsed low grade non-Hodgkin's lymphoma.
September 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
C J Coonley, and R P Warrell, and D J Straus, and C W Young
Clinical evaluation of a new anthracycline antibiotic, aclacinomycin-A, in patients with advanced malignant lymphoma.
February 1983, American journal of clinical oncology,
C J Coonley, and R P Warrell, and D J Straus, and C W Young
Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin.
October 1985, European journal of cancer & clinical oncology,
C J Coonley, and R P Warrell, and D J Straus, and C W Young
Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer.
January 1988, Acta oncologica (Stockholm, Sweden),
C J Coonley, and R P Warrell, and D J Straus, and C W Young
Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
June 1987, Cancer research,
C J Coonley, and R P Warrell, and D J Straus, and C W Young
Clinical pharmacology of 4-demethoxydaunorubicin (DMDR).
January 1986, Cancer chemotherapy and pharmacology,
C J Coonley, and R P Warrell, and D J Straus, and C W Young
Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
December 1983, Cancer research,
C J Coonley, and R P Warrell, and D J Straus, and C W Young
Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients.
January 1990, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!